Skip to main content
Premium Trial:

Request an Annual Quote

MetaStat Effects One-for-15 Reverse Stock Split

NEW YORK (GenomeWeb) – MetaStat today effected a one-for-15 reverse stock split with an eye toward listing its shares on a national securities exchange. 

The shares began trading today on a post-split basis on the OTCQB under the temporary symbol "MTSTD". MetaStat's board approved the reverse stock split in January, and its shareholders approved the move in June. 

MetaStat President and CEO Douglas Hamilton said in a statement that the action is aimed at increasing the liquidity and visibility of the company's stock. "Uplisting to a national securities exchange will allow greater access to capital to help commercialize our first product offering and expand the depth and breadth of our product pipeline." 

The company previously told GenomeWeb that it plans to launch its MetaSite Breast and MenaCalc assays next year as prognostic tools for ER-positive, HER2-negative patients. The tests are for stratifying patients based on their tumor's aggressiveness and the risk that their cancers will spread. 

MetaStat last week announced it had received Massachusetts licensure for its digital pathology laboratory in Boston.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more